Related Experiment Videos
Apolipoprotein E mimetic peptide, CN-105, improves outcomes in ischemic stroke
Tian Ming Tu1, Brad J Kolls2, Erik J Soderblom3
1Department of Neurology Duke University School of Medicine Durham North Carolina; Department of Neurology National Neuroscience Institute Tan Tock Seng Campus Singapore.
Annals of Clinical and Translational Neurology
|April 7, 2017
Summary
The apolipoprotein E mimetic pentapeptide CN-105 shows neuroprotective effects against ischemic stroke in mice. It improves survival, function, and reduces brain damage by modulating neuroinflammation.
Area of Science:
- Neuroscience
- Pharmacology
- Stroke Research
Background:
- Ischemic and traumatic brain injuries lack effective pharmacological neuroprotectants.
- Apolipoprotein E (ApoE) mimetic therapies show promise for neuroprotection.
- CN-105 is a novel ApoE mimetic pentapeptide.
Purpose of the Study:
- To investigate the neuroprotective and anti-inflammatory properties of CN-105.
- To evaluate CN-105 in a murine model of ischemic stroke and in vitro microglial cells.
- To explore the mechanistic pathways of CN-105 action.
Main Methods:
- Transient middle cerebral artery occlusion in C57/BL6 mice.
- Administration of CN-105 or vehicle via tail vein injection.
- Assessment of survival, functional outcomes, infarct volume, microglial activation, and cytokine secretion.
Main Results:
- CN-105 significantly improved survival and functional outcomes in mice.
- Reduced infarct volume and microglial activation were observed with CN-105 treatment.
- In vitro studies showed CN-105 suppressed inflammatory cytokine secretion and reduced oxidative stress.
Conclusions:
- CN-105 demonstrates significant neuroprotective and anti-inflammatory effects in ischemic stroke.
- The compound modulates neuroinflammatory pathways and reduces oxidative stress.
- CN-105 shows potential for clinical translation due to favorable safety and pharmacokinetic profiles.